Unknown

Dataset Information

0

Recombinant PAL/PilE/FlaA DNA vaccine provides protective immunity against Legionella pneumophila in BALB/c mice.


ABSTRACT: BACKGROUND:Legionella pneumophila (L.pneumophila), a Gram-negative small microorganism, causes hospital-acquired pneumonia especially in immunocompromised patients. Vaccination may be an effective method for preventing L.pneumophila infection. Therefore, it is necessary to develop a better vaccine against this disease. In this study, we developed a recombinant peptidoglycan-associated lipoprotein (PAL)/type IV pilin (PilE)/lagellin (FlaA) DNA vaccine and evaluated its immunogenicity and efficacy to protect against L.pneumophila infection. RESULTS:According to the results, the expression of PAL, PilE, FlaA proteins and PAL/PilE/FlaA fusion protein in 293 cells was confirmed. Immunization with PAL/PilE/FlaA DNA vaccine resulted in highest IgG titer and strongest cytotoxic T-lymphocyte (CTL) response. Furthermore, the histopathological changes in lung tissues of mice challenged with a lethal dose of L.pneumophila were alleviated by PAL/PilE/FlaA DNA vaccine immunization. The production of T-helper-1 (Th1) cytokines (IFN?, TGF-?, and IL-12), and Th2 cytokines (IL-4 and IL-10) were promoted in PAL/PilE/FlaA DNA vaccine group. Finally, immunization with PAL/PilE/FlaA vaccine raised the survival rate of mice to 100% after challenging with a lethal dose of L.pneumophila for 10 consecutive days. CONCLUSIONS:Our study suggests that the newly developed PAL/PilE/FlaA DNA vaccine stimulates strong humoral and cellular immune responses and may be a potential intervention on L.pneumophila infection.

SUBMITTER: Chen Y 

PROVIDER: S-EPMC7236329 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Recombinant PAL/PilE/FlaA DNA vaccine provides protective immunity against Legionella pneumophila in BALB/c mice.

Chen Yingying Y   Yang Zehui Z   Dong Ying Y   Chen Yu Y  

BMC biotechnology 20200518 1


<h4>Background</h4>Legionella pneumophila (L.pneumophila), a Gram-negative small microorganism, causes hospital-acquired pneumonia especially in immunocompromised patients. Vaccination may be an effective method for preventing L.pneumophila infection. Therefore, it is necessary to develop a better vaccine against this disease. In this study, we developed a recombinant peptidoglycan-associated lipoprotein (PAL)/type IV pilin (PilE)/lagellin (FlaA) DNA vaccine and evaluated its immunogenicity and  ...[more]

Similar Datasets

| S-EPMC9670971 | biostudies-literature
| S-EPMC173334 | biostudies-other
| S-EPMC7163142 | biostudies-literature
| S-EPMC6329706 | biostudies-literature
| S-EPMC3678716 | biostudies-literature
| S-EPMC1828979 | biostudies-literature
| S-EPMC3310633 | biostudies-literature
| S-EPMC3536254 | biostudies-literature
| S-EPMC10133462 | biostudies-literature
2015-11-13 | PXD001926 | Pride